The effect of low dose caffeine powder supplementation on serve speed, spike speed, and speed-endurance in elite sitting volleyball players: a randomized double-blind crossover study


Creative Commons License

Diedhiou A. B., Erkan D., Guler M., Sar H., Karakulak I., Eyuboglu E., ...Daha Fazla

BMC Sports Science, Medicine and Rehabilitation, cilt.17, sa.1, 2025 (SCI-Expanded, Scopus) identifier identifier

Özet

Background: Sitting volleyball relies heavily on upper-body strength and anaerobic capacity. Serve, spike, and speed-endurance are decisive skills, yet the ergogenic potential of low-dose caffeine in this Paralympic sport remains unclear. Purpose: To examine the acute effects of low-dose caffeine (3 mg/kg) supplementation on serve speed, spike speed, and speed-endurance in elite sitting volleyball players. Methods: Using a randomized, double-blind, crossover design, 13 elite male athletes from the Turkish National Sitting Volleyball Team completed serve speed, spike speed, and speed-endurance tests under caffeine (CAF) and placebo (PLA) conditions. Results: Caffeine intake produced a moderate improvement in serve speed (p = 0.028, d = 0.460); however, this effect did not remain statistically significant after Bonferroni correction (adjusted p = 0.084). No significant effects were observed for spike speed (p = 0.547, d = 0.166) or speed-endurance performance (p = 0.709, d = 0.111). Perceived exertion during the speed-endurance test was similarly high in both conditions. Conclusions: Low-dose caffeine may offer a trend toward improved serve performance, but the effect was not robust after statistical adjustment, and no benefits were observed for spike speed or speed-endurance. These findings highlight that caffeine’s ergogenic effects are context-dependent and shaped by task complexity and sport-specific motor demands. Further research with larger and more diverse samples, genotype-based subgroups, and varied dosing strategies is warranted to clarify caffeine’s role in adaptive sports. Trial registration: The randomized controlled trial was retrospectively registered on 21/06/2025 at ClinicalTrials.gov, under the registration number NCT07056231.